Biomarker and Diagnostics Strategy

This is where precision medicine starts – whether you’re trying to find the right tools to uncover new biomarkers, identify CDx partners, launch an IVD, or understand how your assay will fit into the clinical journey, DeciBio has you covered. Nobody knows biomarkers and CDx better than DeciBio.

Our Experts

Andrew Aijian

Stephane Budel

David Cavanaugh

David Cavanaugh

Schedule a Call

Related Client Results

All Client Results

Financial Services

PE-Backed Life Sciences Tools Platform Development

A leading private equity firm and management team sought out DeciBio as a strategic partner to advise on the life sciences market and perform due-diligences in support of the development of a novel life sciences tools platform

Voice-of-Customer Research

Customer Segmentation

Pricing Strategy

Due Diligence

Competitive Analysis

Pharma & Biotech

Healthcare IT Solution Market Opportunity

A leading pharmaceutical & clinical diagnostics manufacturer wanted to understand the market opportunity for a novel multidisciplinary cancer conference IT support solution

Voice-of-Customer Research

Go-to-Market Strategy

Competitive Analysis

Pharma & Biotech

Cell Therapy Market Trends and Revenue Forecast

DeciBio conducted financial projections, valuation, and assisted with messaging to aid client's public listing to NASDAQ

Revenue Projection

Clinical Diagnostics

New Prenatal Opportunity Assessment

A multinational pharmaceutical and diagnostics company was interested in learning more about the U.S. market opportunity for their novel noninvasive prenatal test in development

Voice-of-Customer Research

Go-to-Market Strategy

Clinical Diagnostics

Diagnostic Advisory Board

A diagnostics company requested DeciBio to help an advisory board (ad board) to understand how to position its relatively new somatic oncology genomics profiling product in an already competitive market

Voice-of-Customer Research

KOL Identification

Pharma & Biotech

Early-Stage Cancer Biomarker Testing and Treatment Landscape Assessment

A top-10 biopharma wanted to assess how the biomarker testing and treatment landscape would change, and the potential impact on the use of their drug, in response to a recent approval of a new competing cancer therapy approved in earlier lines of treatment

Competitive Analysis

Voice-of-Customer Research

Precision Medicine is evolving at a rapid pace

Discover how we can help